Jpmorgan Chase & Co »

Alnylam Pharmaceuticals Inc Note 1.000 9/1 shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Alnylam Pharmaceuticals Inc Note 1.000 9/1 shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Alnylam Pharmaceuticals Inc Note 1.000 9/1

Tip: Access up to 7 years of quarterly data

All positions including Alnylam Pharmaceuticals Inc Note 1.000 9/1 held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alnylam Pharmaceuticals Inc Note 1.000 9/1 by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2023-12-31 $114k 115k 0.99
2023-09-30 $492k 530k 0.93

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Apple Common (AAPL)
Amazon Common (AMZN)
Spdr S&p 500 Etf Trust Fund (SPY)
Nvidia Corporation Common (NVDA)
Meta Platforms Common (META)
Unitedhealth Group Common (UNH)
Vanguard Total Intl Bond Etf Fund (BNDX)
Alphabet Common (GOOG)
Eli Lilly & Co Common (LLY)
Mastercard Incorporated Common (MA)
Alphabet Common (GOOGL)
Abbvie Common (ABBV)
Vanguard Total Bond Market Fund (BND)
Tesla Common (TSLA)

View all positions for Jpmorgan Chase & Co

Top funds holding Alnylam Pharmaceuticals Inc Note 1.000 9/1

Ubs Global Asset Management Americas
Readystate Asset Management
Steelhead Partners
Calamos Advisors
Aequim Alternative Investments
Davidson Kempner Capital Management
Wolverine Asset Management
Lazard Asset Management
Zazove Associates
Shenkman Capital Management
CNH Partners
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Capstone Investment Advisors
Citadel Advisors
MacKay Shields

View all funds holding Alnylam Pharmaceuticals Inc Note 1.000 9/1